Safety and Tolerability of Etanercept in Alzheimer's Disease

Phase 2 Completed 41 enrolled University of Southampton Hampshire Hospitals NHS Foundation Trust · collab Wyeth is now a wholly owned subsidiary of Pfizer · collab

RandomizedSingle-groupQuadruple-blindTreatment

Summary

The primary aim of the study is to determine the safety and tolerability of etanercept in subjects with Alzheimer's Disease. The effects of etanercept on cognitive, behavioural, functional and immunological outcomes will be examined as secondary aims.

Timeline

Start: 2011-01
Primary completion: 2013-12
Completion: —

Publications

Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, Sharples R, Sharif S, McFarlane B, Raybould R, Thomas R, Passmore P, Perry VH, Holmes C. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015 May 26;84(21):2161-8. doi: 10.1212/WNL.0000000000001617. Epub 2015 May 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	50 mg	Subcutaneous

Safety and Tolerability of Etanercept in Alzheimer's Disease

Summary

Timeline

Publications

Drugs

Indications